Abstract
Diabetes and hypertension are major contributors to the increasing incidence of progressive renal disease. In addition to more potent antihypertensive agents that block the renin-angiotensin system, drugs that modulate other pathogenetic pathways are also in development. Recent preclinical studies indicate that compounds that interfere with the formation and action of advanced glycation end products may have a role in the treatment and prevention of diabetic nephropathy, as may agents targeting the activity of protein kinase C.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiotensin-Converting Enzyme Inhibitors / pharmacology
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Animals
-
Clinical Trials as Topic
-
Diabetic Nephropathies / complications
-
Diabetic Nephropathies / drug therapy
-
Diabetic Nephropathies / prevention & control
-
Glycation End Products, Advanced / antagonists & inhibitors
-
Glycation End Products, Advanced / metabolism
-
Humans
-
Hypertension / complications
-
Hypertension / drug therapy
-
Hypertension / prevention & control
-
Kidney Diseases / drug therapy*
-
Kidney Diseases / etiology
-
Kidney Diseases / prevention & control
-
Kidney Failure, Chronic / drug therapy
-
Kidney Failure, Chronic / epidemiology
-
Kidney Failure, Chronic / etiology
-
Neprilysin / antagonists & inhibitors
-
Protein Kinase C / antagonists & inhibitors
-
Receptor for Advanced Glycation End Products
-
Receptors, Immunologic / antagonists & inhibitors
-
Renin-Angiotensin System / drug effects
-
Signal Transduction
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Glycation End Products, Advanced
-
Receptor for Advanced Glycation End Products
-
Receptors, Immunologic
-
Protein Kinase C
-
Neprilysin